PSTV earnings / call / takeaways
PSTV Q3 FY26 earnings call: key takeaways
What PSTV said on its earnings call of November 16, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.
By Lician·November 16, 2026·AI-generated from the call transcript and Lician data
- PSTV reported $0.7 million in diagnostic revenue for Q3 2026, with gross billings of $1.55 million. The company reaffirmed its guidance to exit 2026 with an annualized gross billing run rate of $10 million to $12.5 million. (30:00)
What changed since last quarter
- The company raised its guidance for gross billing run rate to $10 million to $12.5 million, up from previous expectations. (31:50)
- The company expects to secure Medicare reimbursement in the first half of 2027, aligning with its previous guidance. (26:46)
- The company plans to start a randomized Phase IIb study in LM in the second half of 2027, consistent with its previous plans. (35:06)
What analysts pressed on
In their words
We expect to exit 2026 at an annualized gross billings run rate of approximately $10 million to $12.5 million.
Andrew Sims (31:50)We expect to hit that positive contribution at that higher revenue number that I just outlined.
(47:11)We've broken the ceiling from phase one and to date so far feel very confident we could administer ultimately more radiation.
(40:24)Our capacity is significantly in advance of our current volume.
(45:31)
Read the full transcript with the AI summary, or listen on the company's official webcast.
Every past call in full and transcript search come with Lician Pro.
Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.